ABUS
Arbutus Biopharma CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$859.29M
P/E Ratio
5.24
EPS
$0.83
Beta
0.62
52W High
$5.10
52W Low
$3.04
50-Day MA
$4.36
200-Day MA
$4.33
Dividend Yield
—
Profit Margin
84.00%
Forward P/E
10.25
PEG Ratio
0.00
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Fundamentals
| Revenue (TTM) | $191.44M |
| Gross Profit (TTM) | $171.04M |
| EBITDA | $155.14M |
| Operating Margin | 94.40% |
| Return on Equity | 94.70% |
| Return on Assets | 49.20% |
| Revenue/Share (TTM) | $0.99 |
| Book Value | $1.32 |
| Price-to-Book | 3.29 |
| Price-to-Sales (TTM) | 4.49 |
| EV/Revenue | 3.974 |
| EV/EBITDA | 4.73 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 10055.00% |
| Shares Outstanding | $197.54M |
| Float | $121.37M |
| % Insiders | 20.46% |
| % Institutions | 71.89% |
Historical Volatility
HV 10-Day
32.55%
HV 20-Day
29.75%
HV 30-Day
37.45%
HV 60-Day
41.89%
HV Rank
24.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.14 target)
1
Strong Buy2
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026